{"id":"https://openalex.org/W3179699404","doi":"https://doi.org/10.1158/1538-7445.am2021-1224","title":"Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers","display_name":"Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers","publication_year":2021,"publication_date":"2021-07-01","ids":{"openalex":"https://openalex.org/W3179699404","doi":"https://doi.org/10.1158/1538-7445.am2021-1224","mag":"3179699404"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2021-1224","doi":"https://doi.org/10.1158/1538-7445.am2021-1224","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2021-1224","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079460736","display_name":"Richard C. Centore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard C. Centore","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073459416","display_name":"Luis Miguel Mendes Soares","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luis M. Soares","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055870186","display_name":"Rishi G. Vaswani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rishi G. Vaswani","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041831440","display_name":"Kana Ichikawa","orcid":"https://orcid.org/0000-0002-7170-1571","observed_orcids":["https://orcid.org/0000-0002-7170-1571"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kana Ichikawa","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100656420","display_name":"Zhifang Li","orcid":"https://orcid.org/0000-0001-8398-7338","observed_orcids":["https://orcid.org/0000-0001-8398-7338"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhifang Li","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076293392","display_name":"Hong Bo Fan","orcid":"https://orcid.org/0000-0002-3370-7833","observed_orcids":["https://orcid.org/0000-0002-3370-7833"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Fan","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053740902","display_name":"Jeremy W. Setser","orcid":"https://orcid.org/0000-0002-2032-6740","observed_orcids":["https://orcid.org/0000-0002-2032-6740"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy Setser","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078970169","display_name":"David L. Lahr","orcid":"https://orcid.org/0000-0001-6283-0286","observed_orcids":["https://orcid.org/0000-0001-6283-0286"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David L. Lahr","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011537602","display_name":"Laura E. Zawadzke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Zawadzke","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088691885","display_name":"Xueying Chen","orcid":"https://orcid.org/0009-0005-9061-3111","observed_orcids":["https://orcid.org/0009-0005-9061-3111","https://orcid.org/0000-0002-5167-3550"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xueying Chen","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012779175","display_name":"Kimberly D. Barnash","orcid":"https://orcid.org/0000-0002-0918-7188","observed_orcids":["https://orcid.org/0000-0002-0918-7188"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberly D. Barnash","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074139173","display_name":"Jordana Muwanguzi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordana Muwanguzi","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108510682","display_name":"Neville J. Anthony","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neville Anthony","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045201129","display_name":"Gabriel J. Sandoval","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel J. Sandoval","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069979455","display_name":"Katharine Feldman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katharine Feldman","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024517878","display_name":"Ammar Adam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ammar Adam","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040208750","display_name":"David C.S. Huang","orcid":"https://orcid.org/0000-0002-3101-4873","observed_orcids":["https://orcid.org/0000-0002-3101-4873"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Huang","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028990126","display_name":"Shawn Schiller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shawn Schiller","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5132853208","display_name":"Kevin Wilson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Wilson","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085300960","display_name":"Johannes H. Voigt","orcid":"https://orcid.org/0009-0000-3912-8595","observed_orcids":["https://orcid.org/0009-0000-3912-8595"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Johannes Voigt","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047249666","display_name":"Martin F. Hentemann","orcid":"https://orcid.org/0009-0008-5657-2151","observed_orcids":["https://orcid.org/0009-0008-5657-2151"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Hentemann","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018290375","display_name":"David S. Millan","orcid":"https://orcid.org/0000-0001-5590-7273","observed_orcids":["https://orcid.org/0000-0001-5590-7273"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Millan","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105367150","display_name":"Ho Man Chan","orcid":"https://orcid.org/0000-0002-1117-1230","observed_orcids":["https://orcid.org/0000-0002-1117-1230"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ho Man Chan","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086182257","display_name":"Steven F. Bellon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven F. Bellon","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044857121","display_name":"Carl P. Decicco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carl P. Decicco","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112319765","display_name":"Lan Xu","orcid":"https://orcid.org/0000-0002-7740-5482","observed_orcids":["https://orcid.org/0000-0002-7740-5482"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lan Xu","raw_affiliation_strings":["Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210164523"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"81","issue":"13_Supplement","first_page":"1224","last_page":"1224"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10222","display_name":"Genomics and Chromatin Dynamics","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chromatin-remodeling","display_name":"chromatin remodeling","score":0.7350000143051147},{"id":"https://openalex.org/keywords/swi-snf-complex","display_name":"SWI/SNF complex","score":0.8330000042915344},{"id":"https://openalex.org/keywords/brg1","display_name":"SMARCA4","score":0.9160000085830688},{"id":"https://openalex.org/keywords/smarca2","display_name":"SMARCA2","score":0.9739999771118164},{"id":"https://openalex.org/keywords/brm","display_name":"BRM","score":0.9900000095367432},{"id":"https://openalex.org/keywords/allosteric-inhibition","display_name":"allosteric inhibition","score":0.7839999794960022},{"id":"https://openalex.org/keywords/uveal-melanoma","display_name":"uveal melanoma","score":0.8539999723434448},{"id":"https://openalex.org/keywords/hematological-cancer","display_name":"hematologic cancer","score":0.8009999990463257},{"id":"https://openalex.org/keywords/sox10","display_name":"SOX10","score":0.9589999914169312},{"id":"https://openalex.org/keywords/mitf","display_name":"MITF","score":0.9990000128746033},{"id":"https://openalex.org/keywords/enhancer-accessibility","display_name":"enhancer accessibility","score":0.6240000128746033},{"id":"https://openalex.org/keywords/transcription-factor-binding","display_name":"transcription factor binding","score":0.6990000009536743},{"id":"https://openalex.org/keywords/melanocyte-differentiation","display_name":"melanocyte differentiation","score":0.8180000185966492},{"id":"https://openalex.org/keywords/tumor-regression","display_name":"tumor regression","score":0.5149999856948853},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7310000061988831},{"id":"https://openalex.org/keywords/chromatin-accessibility","display_name":"chromatin accessibility","score":0.48399999737739563}],"concepts":[{"id":"https://openalex.org/C177504595","wikidata":"https://www.wikidata.org/wiki/Q336500","display_name":"Microphthalmia-associated transcription factor","level":4,"score":0.8804489374160767},{"id":"https://openalex.org/C80828422","wikidata":"https://www.wikidata.org/wiki/Q18031595","display_name":"SMARCA4","level":5,"score":0.7551045417785645},{"id":"https://openalex.org/C83640560","wikidata":"https://www.wikidata.org/wiki/Q180951","display_name":"Chromatin","level":3,"score":0.7281708717346191},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.6669930219650269},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6015768647193909},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5860199332237244},{"id":"https://openalex.org/C2777302934","wikidata":"https://www.wikidata.org/wiki/Q18031655","display_name":"SOX10","level":4,"score":0.5311656594276428},{"id":"https://openalex.org/C167227067","wikidata":"https://www.wikidata.org/wiki/Q5113739","display_name":"Chromatin remodeling","level":4,"score":0.5274971723556519},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5102097988128662},{"id":"https://openalex.org/C111936080","wikidata":"https://www.wikidata.org/wiki/Q913367","display_name":"Enhancer","level":4,"score":0.4886096119880676},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.416381299495697},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3708402216434479},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.3259074091911316},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.2616027593612671}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2021-1224","doi":"https://doi.org/10.1158/1538-7445.am2021-1224","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2021-1224","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4416147282","https://openalex.org/W4387810962","https://openalex.org/W4414676679","https://openalex.org/W4400775368","https://openalex.org/W4393090491","https://openalex.org/W4399505157","https://openalex.org/W7147676273","https://openalex.org/W2478338916","https://openalex.org/W2969861110","https://openalex.org/W7002039303"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"BRG/Brahma-associated":[2],"factors":[3,207],"(BAF)":[4],"family":[5],"of":[6,21,34,41,50,64,74,105,125,147,156,162,178,184,216,235,247,324,331,338],"chromatin":[7,19,27,114],"remodeling":[8,28],"complexes":[9],"(also":[10,81],"referred":[11],"to":[12,141,255],"as":[13,251],"the":[14,18,22,32,39,71,75,106,145,154,159,163,174,195,242,329,339],"mSWI/SNF":[15],"complex)":[16],"regulates":[17,31],"landscape":[20],"genome.":[23],"Through":[24],"its":[25],"ATP-dependent":[26],"activity,":[29],"BAF":[30,45,76,107,142,150,191,219,248,326],"accessibility":[33,115,157],"gene-control":[35],"elements,":[36],"allowing":[37],"for":[38,244,328,342],"binding":[40,160],"transcription":[42,167,206,332],"factors.":[43],"Thus,":[44],"is":[46],"a":[47,61,99,212,252],"major":[48],"regulator":[49],"lineage-":[51],"and":[52,59,68,79,84,89,133,165,176,186,193,197,224,351],"disease-specific":[53],"transcriptional":[54],"programs.":[55],"We":[56],"have":[57],"discovered":[58],"developed":[60],"novel":[62,253,325],"series":[63],"compounds":[65],"that":[66,93,130,230],"potently":[67],"selectively":[69],"inhibits":[70],"ATPase":[72,249],"components":[73],"complex,":[77],"SMARCA4":[78],"SMARCA2":[80],"called":[82],"BRG1":[83],"BRM,":[85],"respectively).":[86],"Mutational,":[87],"structural,":[88],"biochemical":[90],"studies":[91,246],"demonstrated":[92],"these":[94,204],"SMARCA4/SMARCA2":[95],"inhibitors":[96,327],"act":[97],"through":[98],"unique":[100],"allosteric":[101],"mechanism.":[102],"Pharmacologic":[103],"inhibition":[104,151,220,250],"complex":[108],"resulted":[109,152,225],"in":[110,113,116,153,172,211,226],"lineage-specific":[111],"changes":[112],"cancer":[117,126,135],"cell":[118,127,136],"lines":[119,128,137],"from":[120],"diverse":[121],"origins.":[122],"Phenotypic":[123],"screening":[124],"showed":[129],"uveal":[131,148,179,217,257],"melanoma":[132,180],"hematological":[134],"were":[138],"exquisitely":[139],"sensitive":[140],"inhibition.":[143],"In":[144],"example":[146],"melanoma,":[149,218],"loss":[155],"at":[158],"sites":[161],"SOX10":[164,185],"MITF":[166,187],"factors,":[168],"two":[169],"essential":[170],"proteins":[171],"supporting":[173],"proliferation":[175],"survival":[177],"cells.":[181],"Enhancer":[182],"occupancy":[183],"was":[188,208,221],"reduced":[189],"upon":[190],"inhibition,":[192],"subsequently,":[194],"melanocytic":[196],"pigmentation":[198],"gene":[199,237],"expression":[200],"program":[201],"regulated":[202],"by":[203],"master":[205],"suppressed.":[209],"Finally,":[210],"mouse":[213],"xenograft":[214],"model":[215],"well":[222],"tolerated":[223],"dose-dependent":[227],"tumor":[228],"regression":[229],"correlated":[231],"with":[232],"pharmacodynamic":[233],"modulation":[234],"BAF-target":[236],"expression.":[238],"These":[239],"data":[240],"provide":[241],"foundation":[243],"first-in-human":[245],"therapeutic":[254],"treat":[256],"melanoma.":[258],"Citation":[259],"Format:":[260],"Richard":[261],"C.":[262],"Centore,":[263],"Luis":[264],"M.":[265],"Soares,":[266],"Rishi":[267],"G.":[268],"Vaswani,":[269],"Kana":[270],"Ichikawa,":[271],"Zhifang":[272],"Li,":[273],"Hong":[274],"Fan,":[275],"Jeremy":[276],"Setser,":[277],"David":[278,299,309],"L.":[279],"Lahr,":[280],"Laura":[281],"Zawadzke,":[282],"Xueying":[283],"Chen,":[284],"Kimberly":[285],"D.":[286],"Barnash,":[287],"Jordana":[288],"Muwanguzi,":[289],"Neville":[290],"Anthony,":[291],"Gabriel":[292],"J.":[293],"Sandoval,":[294],"Katharine":[295],"Feldman,":[296],"Ammar":[297],"Adam,":[298],"Huang,":[300],"Shawn":[301],"Schiller,":[302],"Kevin":[303],"Wilson,":[304],"Johannes":[305],"Voigt,":[306],"Martin":[307],"Hentemann,":[308],"S.":[310],"Millan,":[311],"Ho":[312],"Man":[313],"Chan,":[314],"Steven":[315],"F.":[316],"Bellon,":[317],"Carl":[318],"P.":[319],"Decicco,":[320],"Lan":[321],"Xu.":[322],"Discovery":[323],"treatment":[330],"factor-driven":[333],"cancers":[334],"[abstract].":[335],"In:":[336],"Proceedings":[337],"American":[340],"Association":[341],"Cancer":[343,357],"Research":[344],"Annual":[345],"Meeting":[346],"2021;":[347],"2021":[348],"Apr":[349],"10-15":[350],"May":[352],"17-21.":[353],"Philadelphia":[354],"(PA):":[355],"AACR;":[356],"Res":[358],"2021;81(13_Suppl):Abstract":[359],"nr":[360],"1224.":[361]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2021-07-19T00:00:00"}